Amedisys, Inc. (NASDAQ:AMED) Given Average Rating of “Hold” by Brokerages

Amedisys, Inc. (NASDAQ:AMED) has received a consensus rating of “Hold” from the six brokerages that are currently covering the stock, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $100.75.

Separately, Stephens reiterated an “equal weight” rating and issued a $101.00 price target on shares of Amedisys in a research report on Tuesday, March 4th.

Amedisys Trading Down 0.0 %

NASDAQ:AMED opened at $92.57 on Friday. The stock has a market capitalization of $3.04 billion, a price-to-earnings ratio of 36.73, a PEG ratio of 1.78 and a beta of 0.76. Amedisys has a 12 month low of $82.15 and a 12 month high of $98.95. The firm has a fifty day simple moving average of $92.14 and a two-hundred day simple moving average of $92.78. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Wednesday, February 26th. The health services provider reported $0.96 EPS for the quarter, missing the consensus estimate of $1.05 by ($0.09). The firm had revenue of $598.05 million during the quarter, compared to analysts’ expectations of $602.38 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. Analysts expect that Amedisys will post 4.4 EPS for the current fiscal year.

Hedge Funds Weigh In On Amedisys

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AMED. Blue Trust Inc. grew its position in Amedisys by 55.1% during the fourth quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock valued at $34,000 after buying an additional 124 shares during the period. HBW Advisory Services LLC purchased a new position in Amedisys during the fourth quarter worth $38,000. Versant Capital Management Inc lifted its stake in shares of Amedisys by 68.5% during the 4th quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock worth $41,000 after acquiring an additional 183 shares during the last quarter. Johnson Financial Group Inc. purchased a new stake in shares of Amedisys in the fourth quarter valued at approximately $55,000. Finally, KBC Group NV bought a new position in shares of Amedisys during the third quarter valued at approximately $63,000. 94.36% of the stock is owned by institutional investors.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.